QGEN Qiagen N.V.

Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company’s rapid sepsis testing portfolio in a single automated system. Qiagen’s latest FDA clearance lands after a period of mixed trading, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. Scan how Qiagen’s...

Earlier this week, QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, complementing an existing gram-positive and fungal panel and expanding its syndromic infectious disease testing menu. This clearance materially broadens QIAGEN’s coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated...

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

Qiagen (NYSE:QGEN) shares gained 4% on Thursday morning following a media report that several private equity firms are considering potential offers for the molecular testing company. German publication Manager Magazin reported that TPG and Bain Capital are among the firms weighing bids for Qiagen, although it did not identify sources for the information.

On August 27, QIAGEN N.V. (NYSE:QGEN) launched QIAsymphony Connect, a new automated platform for clinical nucleic acid extraction aimed at laboratories running liquid biopsy, oncology, and infectious disease tests. The timing is notable. On August 5, QIAGEN had already posted second-quarter results that beat its own guidance, with growth pillars like Sample technologies and QIAcuity […]

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

European indexes were mixed in quiet early trade. Healthcare and consumer-facing stocks struggled, though AI-related stocks gained.

Qiagen (QGEN) has drawn fresh attention after Q2 2026 adjusted earnings and net sales came in above consensus, even as estimates had recently drifted lower, and management reaffirmed its full year outlook. The Q2 beat and reaffirmed guidance contrast with a mixed share price backdrop for Qiagen, with the stock closing at US$43.47 after a daily share price return that slipped 0.89% but a 90 day share price return of 18.51% pointing to improving momentum. Capitalize on Qiagen's earnings...

In late August 2026, Qiagen launched QIAsymphony Connect, an IVD-compliant automated nucleic acid extraction platform with FDA and EUDAMED listings, while also announcing a CEO transition to Jon Pratt from September 1 and reporting Q2 2026 results that exceeded analyst expectations with reaffirmed guidance. The combination of a next-generation automation platform, leadership change and better-than-expected quarterly performance highlights how Qiagen is tightening its focus on high-throughput...

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

Qiagen N.V. (NYSE:QGEN) announced on August 10 that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, marking the company’s first entry into the U.S. bloodstream infection testing market. Operating on the QIAstat-Dx platform, which boasts over 5,200 global placements, the automated panel detects 20 gram-positive bacterial and fungal targets, alongside 10 genetic […]

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Str

Jonathan Pratt will take over the role on Sept. 1. The announcement ends Qiagen’s nearly 10-month search for a new chief executive.

Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with potential buyers.

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year guidance, along with FDA clearance for its QIAstat Dx BCID GPF Plus AMR Panel. See our latest analysis for Qiagen. The recent Q2 beat, reaffirmed guidance and FDA clearance appear to have supported sentiment in Qiagen, with the stock at US$43.23 and a 90 day share price return of 31.08% contrasting with a year to date share price decline of 9.12% and a 1 year total...

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company’s own outlook. For a diagnostics and life sciences supplier still working through the loss of […]

Zillow Group (NASDAQ:Z) delivered a second quarter that beat its own outlook on nearly every line, then turned around and eliminated jobs and reshuffled its leadership team. On the call held August 5, CEO Jeremy Wacksman and newly expanded COO and CFO Jeremy Hofmann laid out a business growing far faster than the housing market […]

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. On August 10, 2026, the company also secured U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, moving its QIAstat-Dx platform into bloodstream infection diagnostics and...

Sales beat guidance as Sample Technologies and QIAcuity drive growth momentum.

Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Qiagen (NYSE:QGEN) reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings pe

Moby summary of Qiagen N.V.'s Q2 2026 earnings call

Qiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?